KLK3 and posterior cortical atrophy: Therefore, it is of high priority to supplement the actual PSA testing technology with more sensitive and robust PCa biomarkers in order to reduce overtreatment, and additionally consider more often active surveillance [4] and preserving therapies, e.g., high-intensity focal ultrasound (HIFU).